Results 11 to 20 of about 305,001 (288)
Hematology, 2004 AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone +2 more
openaire +3 more sources
Advances in acute myeloid leukemia [PDF]
BMJ, 2021 ABSTRACTAcute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and disease progression have led to novel therapies for AML.
Laura F, Newell, Rachel J, Cook
openaire +2 more sources
Congenital acute myeloid leukemia with unique translocation t(11;19)(q23;p13.3) [PDF]
, 2015 Congenital leukemia is rarely encountered in clinical practice, even in tertiary children's hospitals. Leukemia may cause significant coagulopathy, putting the patient at risk of intracranial hemorrhage.
Bandt, S. Kathleen +8 more
core +3 more sources
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
Haematologica, 2012 Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali +10 more
doaj +1 more source
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source
Genomics of Acute Myeloid Leukemia [PDF]
The Cancer Journal, 2011 The acute myeloid leukemia (AML) genome has been the subject of intensive research over the past 4 decades. New technologies, enabling characterization of the AML genome at increased resolution, have revealed deeper layers of complexity that have provided insights into the biological basis of this disease, nominated targets for therapy, and identified ...
Timothy A, Graubert, Elaine R, Mardis
openaire +2 more sources
Haematologica, 2010 Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao +6 more
doaj +1 more source
Haematologica, 2008 Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini +12 more
doaj +1 more source
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling [PDF]
, 2018 Trib2 pseudokinase is involved in the etiology of a number of cancers including leukaemia, melanoma, ovarian, lung and liver cancer. Both high and low Trib2 expression levels correlate with different types of cancer.
Carmody, Ruaidhri J. +6 more
core +2 more sources
Haematologica, 2012 The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried +9 more
doaj +1 more source